protein

Recombinant Viral CMV UL146/vCXC1 Protein

620-CM-025

25 ug

423 USD

620-CM

620-CM-025

Recombinant Viral CMV UL146/vCXC1 Protein

The Recombinant Viral CMV UL146/vCXC1 Protein from R&D Systems is derived from E. coli. The Recombinant Viral CMV UL146/vCXC1 Protein has been validated for the following applications: Bioactivity.

UL146/vCXC1

Proteins and Enzymes

25 ug

Lyophilized from a 0.2 µm filtered solution in Acetonitrile and TFA with BSA as a carrier protein.

Unconjugated

>97%, by SDS-PAGE under reducing conditions and visualized by silver stain

Viral

11.1 kDa

Measured by its ability to induce myeloperoxidase release from cytochalasin B-treated human neutrophils. Schröder, J.M. et al . (1987) J. Immunol. 139 :3474. The ED50 for this effect is 0.3-0.6 µg/mL. Measured by its ability to chemoattract BaF3 mouse pro-B cells transfected with human CXCR2. The ED50 for this effect is 0.03-0.18 µg/mL.

<0.10 EU per 1 µg of the protein by the LAL method.

AAA85885

Bioactivity

E. coli-derived Recombinant Viral CMV UL146/vCXC1 Protein

423 USD

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution.